JP2008516930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008516930A5 JP2008516930A5 JP2007536186A JP2007536186A JP2008516930A5 JP 2008516930 A5 JP2008516930 A5 JP 2008516930A5 JP 2007536186 A JP2007536186 A JP 2007536186A JP 2007536186 A JP2007536186 A JP 2007536186A JP 2008516930 A5 JP2008516930 A5 JP 2008516930A5
- Authority
- JP
- Japan
- Prior art keywords
- aza
- bicyclo
- pyridazin
- yloxy
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000003118 aryl group Chemical group 0.000 claims 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 12
- -1 cyano, amino Chemical group 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 11
- 125000001475 halogen functional group Chemical group 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 10
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000004952 trihaloalkoxy group Chemical group 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 9
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 9
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 7
- 125000002837 carbocyclic group Chemical group 0.000 claims 6
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- XWIFEJCBRIMSJB-UHFFFAOYSA-N 2-[2-[6-(1-azabicyclo[2.2.2]octan-3-yloxy)pyridazin-3-yl]ethynyl]aniline Chemical compound NC1=CC=CC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 XWIFEJCBRIMSJB-UHFFFAOYSA-N 0.000 claims 1
- UNPROPIGVAWRMD-UHFFFAOYSA-N 3-[2-[6-(1-azabicyclo[2.2.2]octan-3-yloxy)pyridazin-3-yl]ethynyl]aniline Chemical compound NC1=CC=CC(C#CC=2N=NC(OC3C4CCN(CC4)C3)=CC=2)=C1 UNPROPIGVAWRMD-UHFFFAOYSA-N 0.000 claims 1
- YNWCPUAHDWIRLJ-UHFFFAOYSA-N 3-[4-(2-phenylethynyl)phenoxy]-1-azabicyclo[2.2.2]octane Chemical compound C1CN(C2)CCC1C2OC(C=C1)=CC=C1C#CC1=CC=CC=C1 YNWCPUAHDWIRLJ-UHFFFAOYSA-N 0.000 claims 1
- HBDKMKSCGQGTQR-UHFFFAOYSA-N 3-[4-[2-(3-fluorophenyl)ethynyl]phenoxy]-1-azabicyclo[2.2.2]octane Chemical compound FC1=CC=CC(C#CC=2C=CC(OC3C4CCN(CC4)C3)=CC=2)=C1 HBDKMKSCGQGTQR-UHFFFAOYSA-N 0.000 claims 1
- PXQPUJNDUJHXRS-UHFFFAOYSA-N 3-[6-(2-naphthalen-2-ylethynyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1=CC=CC2=CC(C#CC3=CC=C(N=N3)OC3C4CCN(C3)CC4)=CC=C21 PXQPUJNDUJHXRS-UHFFFAOYSA-N 0.000 claims 1
- GBCWWFFIDIIHRX-UHFFFAOYSA-N 3-[6-(2-phenylethynyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1CN(C2)CCC1C2OC(N=N1)=CC=C1C#CC1=CC=CC=C1 GBCWWFFIDIIHRX-UHFFFAOYSA-N 0.000 claims 1
- GYEAYFHZMBIDHM-UHFFFAOYSA-N 3-[6-(2-pyridin-2-ylethynyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1CN(C2)CCC1C2OC(N=N1)=CC=C1C#CC1=CC=CC=N1 GYEAYFHZMBIDHM-UHFFFAOYSA-N 0.000 claims 1
- YBVYUFORDATUOZ-UHFFFAOYSA-N 3-[6-(2-pyridin-3-ylethynyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1CN(C2)CCC1C2OC(N=N1)=CC=C1C#CC1=CC=CN=C1 YBVYUFORDATUOZ-UHFFFAOYSA-N 0.000 claims 1
- YKKIATAPPZNTRB-UHFFFAOYSA-N 3-[6-(2-pyridin-4-ylethynyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1CN(C2)CCC1C2OC(N=N1)=CC=C1C#CC1=CC=NC=C1 YKKIATAPPZNTRB-UHFFFAOYSA-N 0.000 claims 1
- MUUUWBFOBOZNAB-UHFFFAOYSA-N 3-[6-(2-thiophen-3-ylethynyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1CN(C2)CCC1C2OC(N=N1)=CC=C1C#CC=1C=CSC=1 MUUUWBFOBOZNAB-UHFFFAOYSA-N 0.000 claims 1
- NJBKKYUSIAGEGD-UHFFFAOYSA-N 3-[6-[2-(2,4-difluorophenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound FC1=CC(F)=CC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 NJBKKYUSIAGEGD-UHFFFAOYSA-N 0.000 claims 1
- AUWPHMPQFLCOOE-UHFFFAOYSA-N 3-[6-[2-(2-chlorophenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound ClC1=CC=CC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 AUWPHMPQFLCOOE-UHFFFAOYSA-N 0.000 claims 1
- VDEPQFNAXXSJAK-UHFFFAOYSA-N 3-[6-[2-(2-fluorophenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound FC1=CC=CC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 VDEPQFNAXXSJAK-UHFFFAOYSA-N 0.000 claims 1
- PCFCQWAICOJBMH-UHFFFAOYSA-N 3-[6-[2-(2-nitrophenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound [O-][N+](=O)C1=CC=CC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 PCFCQWAICOJBMH-UHFFFAOYSA-N 0.000 claims 1
- KBZWDHLBZUNDLT-UHFFFAOYSA-N 3-[6-[2-(3,5-difluorophenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound FC1=CC(F)=CC(C#CC=2N=NC(OC3C4CCN(CC4)C3)=CC=2)=C1 KBZWDHLBZUNDLT-UHFFFAOYSA-N 0.000 claims 1
- NUDYGJZXQFIZHO-UHFFFAOYSA-N 3-[6-[2-(3,5-dimethoxyphenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound COC1=CC(OC)=CC(C#CC=2N=NC(OC3C4CCN(CC4)C3)=CC=2)=C1 NUDYGJZXQFIZHO-UHFFFAOYSA-N 0.000 claims 1
- MGSBBEVEYLNZBM-UHFFFAOYSA-N 3-[6-[2-(3-chlorophenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound ClC1=CC=CC(C#CC=2N=NC(OC3C4CCN(CC4)C3)=CC=2)=C1 MGSBBEVEYLNZBM-UHFFFAOYSA-N 0.000 claims 1
- IDDADLGMXRUAAJ-UHFFFAOYSA-N 3-[6-[2-(3-fluorophenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound FC1=CC=CC(C#CC=2N=NC(OC3C4CCN(CC4)C3)=CC=2)=C1 IDDADLGMXRUAAJ-UHFFFAOYSA-N 0.000 claims 1
- XFWVOBNMDZIXEJ-UHFFFAOYSA-N 3-[6-[2-(3-methylimidazol-4-yl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound CN1C=NC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 XFWVOBNMDZIXEJ-UHFFFAOYSA-N 0.000 claims 1
- NMTHHTUPHIMPMU-UHFFFAOYSA-N 3-[6-[2-(3-nitrophenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound [O-][N+](=O)C1=CC=CC(C#CC=2N=NC(OC3C4CCN(CC4)C3)=CC=2)=C1 NMTHHTUPHIMPMU-UHFFFAOYSA-N 0.000 claims 1
- VBHDJFYVKSCFIO-UHFFFAOYSA-N 3-[6-[2-(4-chlorophenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1=CC(Cl)=CC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 VBHDJFYVKSCFIO-UHFFFAOYSA-N 0.000 claims 1
- PZAILFSUYRYJHR-UHFFFAOYSA-N 3-[6-[2-(4-fluorophenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1=CC(F)=CC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 PZAILFSUYRYJHR-UHFFFAOYSA-N 0.000 claims 1
- UDYNGLMVVWUSRP-UHFFFAOYSA-N 3-[6-[2-(4-methoxyphenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1=CC(OC)=CC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 UDYNGLMVVWUSRP-UHFFFAOYSA-N 0.000 claims 1
- HYLGRIAEGICHPR-UHFFFAOYSA-N 3-[6-[2-(4-nitrophenyl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1=CC([N+](=O)[O-])=CC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 HYLGRIAEGICHPR-UHFFFAOYSA-N 0.000 claims 1
- CGKPBRIKCHMNLK-UHFFFAOYSA-N 3-[6-[2-(6-methoxynaphthalen-2-yl)ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1N(CC2)CCC2C1OC(N=N1)=CC=C1C#CC1=CC2=CC=C(OC)C=C2C=C1 CGKPBRIKCHMNLK-UHFFFAOYSA-N 0.000 claims 1
- VQLKUBDMYNNMRQ-UHFFFAOYSA-N 3-[6-[2-[2-(trifluoromethyl)phenyl]ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound FC(F)(F)C1=CC=CC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 VQLKUBDMYNNMRQ-UHFFFAOYSA-N 0.000 claims 1
- JAIRXOCRPAYPQE-UHFFFAOYSA-N 3-[6-[2-[3-(trifluoromethyl)phenyl]ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound FC(F)(F)C1=CC=CC(C#CC=2N=NC(OC3C4CCN(CC4)C3)=CC=2)=C1 JAIRXOCRPAYPQE-UHFFFAOYSA-N 0.000 claims 1
- XCVKSCYPLKCXCE-UHFFFAOYSA-N 3-[6-[2-[4-(trifluoromethyl)phenyl]ethynyl]pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound C1=CC(C(F)(F)F)=CC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 XCVKSCYPLKCXCE-UHFFFAOYSA-N 0.000 claims 1
- WTIWLMMJSGFSET-UHFFFAOYSA-N 4-[2-[6-(1-azabicyclo[2.2.2]octan-3-yloxy)pyridazin-3-yl]ethynyl]aniline Chemical compound C1=CC(N)=CC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 WTIWLMMJSGFSET-UHFFFAOYSA-N 0.000 claims 1
- GZHOJZSJMKDCQU-UHFFFAOYSA-N 5-[2-[6-(1-azabicyclo[2.2.2]octan-3-yloxy)pyridazin-3-yl]ethynyl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C#CC2=CC=C(N=N2)OC2C3CCN(C2)CC3)=C1 GZHOJZSJMKDCQU-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 230000001856 erectile effect Effects 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 201000009863 inflammatory diarrhea Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 230000029849 luteinization Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- ONEVHQBPAZMHSX-UHFFFAOYSA-N n-[2-[2-[6-(1-azabicyclo[2.2.2]octan-3-yloxy)pyridazin-3-yl]ethynyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 ONEVHQBPAZMHSX-UHFFFAOYSA-N 0.000 claims 1
- NQSGWKIJJNBFSD-UHFFFAOYSA-N n-[3-[2-[6-(1-azabicyclo[2.2.2]octan-3-yloxy)pyridazin-3-yl]ethynyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C#CC=2N=NC(OC3C4CCN(CC4)C3)=CC=2)=C1 NQSGWKIJJNBFSD-UHFFFAOYSA-N 0.000 claims 1
- BATSDJUXECKTBY-UHFFFAOYSA-N n-[4-[2-[6-(1-azabicyclo[2.2.2]octan-3-yloxy)pyridazin-3-yl]ethynyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C#CC(N=N1)=CC=C1OC1C(CC2)CCN2C1 BATSDJUXECKTBY-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000016160 smooth muscle contraction Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61859804P | 2004-10-15 | 2004-10-15 | |
| DKPA200401582 | 2004-10-15 | ||
| PCT/EP2005/055263 WO2006040352A1 (en) | 2004-10-15 | 2005-10-14 | Novel azabicyclic aryl derivatives and their medical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008516930A JP2008516930A (ja) | 2008-05-22 |
| JP2008516930A5 true JP2008516930A5 (https=) | 2008-12-04 |
Family
ID=39509634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007536186A Abandoned JP2008516930A (ja) | 2004-10-15 | 2005-10-14 | 新規なアザ二環式アリール誘導体及びその医学的な使用 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2008516930A (https=) |
| MX (1) | MX2007004245A (https=) |
| NZ (1) | NZ553277A (https=) |
-
2005
- 2005-10-14 JP JP2007536186A patent/JP2008516930A/ja not_active Abandoned
- 2005-10-14 NZ NZ553277A patent/NZ553277A/en not_active IP Right Cessation
- 2005-10-14 MX MX2007004245A patent/MX2007004245A/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009538867A5 (https=) | ||
| JP2008530171A5 (https=) | ||
| JP2008530172A5 (https=) | ||
| JP2009526814A5 (https=) | ||
| JP2009538869A5 (https=) | ||
| JP2009538870A5 (https=) | ||
| JP2008517032A5 (https=) | ||
| CN100432075C (zh) | 作为烟碱样乙酰胆碱受体配体的二氮杂双环芳基衍生物 | |
| JP2009537599A5 (https=) | ||
| NZ538058A (en) | Quinuclidine derivatives and their use for treating disorders related to CNS and PNS | |
| JP2005524713A5 (https=) | ||
| JP2010535738A5 (https=) | ||
| JP2009526814A (ja) | 鏡像異性的に純粋なキヌクリジニルオキシピリダジン、及びニコチン性アセチルコリン受容体リガンドとしてのその使用 | |
| NZ548180A (en) | Diazabicyclic aryl derivatives as cholinergic receptor modulators and nicotinic acetylcholine receptor ligands | |
| EP1562945A1 (en) | 1,4-diazabicyclo(3,2,2)nonane derivatives, preparation and therapeutical use thereof | |
| JP2009526776A5 (https=) | ||
| JP2008530171A (ja) | 新規なジアザ二環系アリール誘導体及びそれらの医療上の使用 | |
| JP2009518357A5 (https=) | ||
| JP2007520525A5 (https=) | ||
| JP2006519208A (ja) | 新規ジアザビシクロアリール誘導体 | |
| JP2007530635A5 (https=) | ||
| WO2006087306A2 (en) | Diazabicyclic aryl derivatives and their use as cholinergic ligands at the nicotinic acetylcholine receptors | |
| JP2006503062A5 (https=) | ||
| RU2008110911A (ru) | Новые диазабициклические арильные производные и их медицинское применение | |
| EP1802616B1 (en) | Novel azabicyclic aryl derivatives and their medical use |